France marketing – Annonce FR http://annonce-fr.com/ Mon, 03 May 2021 02:39:17 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.1 https://annonce-fr.com/wp-content/uploads/2021/04/cropped-icon-32x32.png France marketing – Annonce FR http://annonce-fr.com/ 32 32 Telix Pharmaceuticals appoints Mr. Richard Valeix in EMEA zone https://annonce-fr.com/telix-pharmaceuticals-appoints-mr-richard-valeix-in-emea-zone/ https://annonce-fr.com/telix-pharmaceuticals-appoints-mr-richard-valeix-in-emea-zone/#respond Sun, 02 May 2021 23:15:02 +0000 https://annonce-fr.com/telix-pharmaceuticals-appoints-mr-richard-valeix-in-emea-zone/ MELBOURNE, Australia and HERSTAL, Belgium, May 2, 2021 (GLOBE NEWSWIRE) – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the company) announces today that Mr. Richard Valeix has joined the Telix management team as President, Europe, Middle East and Africa (EMEA). Richard joins Telix with over 20 years of experience in the pharmaceutical industry, including radiopharmaceuticals, gained […]]]>


MELBOURNE, Australia and HERSTAL, Belgium, May 2, 2021 (GLOBE NEWSWIRE) – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the company) announces today that Mr. Richard Valeix has joined the Telix management team as President, Europe, Middle East and Africa (EMEA).

Richard joins Telix with over 20 years of experience in the pharmaceutical industry, including radiopharmaceuticals, gained in senior management positions in a wide range of therapeutic product areas. Before joining Telix, Richard worked at Advanced Accelerator Applications (AAA), a Novartis company where he served for seven years as Managing Director for France, Switzerland, Belgium, the Netherlands and Luxembourg, and global director of marketing and sales. Earlier in his career, Richard held senior sales, marketing and strategy positions at Ipsen and Roche, where he gained extensive experience in European market access, reimbursement, regulatory affairs and regulatory affairs. planning the commercial launch of leading products.

Richard holds a Pharmacist’s degree from the Pharmaceutical University of Marseille (France), a Master in Management from ESC Business School Marseille, and followed the International Marketing Program of INSEAD, Paris ( France).

Telix CEO Dr Christian Behrenbruch said: “I am delighted to welcome Richard to the Telix management team. Richard brings to the company a wealth of experience and a proven track record of successfully launching radiopharmaceuticals that change practice in the diverse market in the EMEA region. Richard’s broad business skills and previous experience are uniquely aligned with preparations for Telix’s European commercial launch for the prostate cancer imaging product Illuccix®and the broader product pipeline that will follow. “

Mr. Valeix added: “Telix has made rapid progress in a short period of time to develop an exciting portfolio of radiopharmaceutical actives that address significant unmet needs in oncology. Having joined Telix, I look forward to working with the team to deliver on the promise of nuclear medicine and ultimately improve outcomes for cancer patients. “

About Telix Pharmaceuticals Limited

Telix is ​​a clinical-stage biopharmaceutical company focused on the development of diagnostics and therapeutics using Targeted Molecular Radiation (TM). Telix is ​​headquartered in Melbourne, Australia, and international operations in Belgium, Japan and the United States. Telix is ​​developing a portfolio of clinical stage products that address significant unmet medical needs in oncology and rare diseases. Telix is ​​listed on the Australian Securities Exchange (ASX: TLX). For more information, visit www.telixpharma.com and follow Telix on Twitter @TelixPharma and LinkedIn.

Telix’s main research product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the US FDA,1 and is undergoing priority review by the Australian Therapeutic Goods Administration (TGA).2 Telix is ​​also advancing Illuccix marketing authorization applications® in the European Union3 and Canada.4 None of the Telix products have received marketing authorization in any jurisdiction.

__________________________
1 ASX Disclosure 11/24/20.
2 ASX Disclosure 04/14/21.
3 ASX Disclosure 5/1/20.
4 ASX Disclosure 12/16/20.



Source link

]]>
https://annonce-fr.com/telix-pharmaceuticals-appoints-mr-richard-valeix-in-emea-zone/feed/ 0
AB Science announced today that its Phase 2B / 3 study of masitinib (AB12003) in metastatic castration-resistant prostate cancer (mCRPC) has met its predefined primary endpoint Paris Stock Exchange: AB https://annonce-fr.com/ab-science-announced-today-that-its-phase-2b-3-study-of-masitinib-ab12003-in-metastatic-castration-resistant-prostate-cancer-mcrpc-has-met-its-predefined-primary-endpoint-paris-stock-exchange-a/ https://annonce-fr.com/ab-science-announced-today-that-its-phase-2b-3-study-of-masitinib-ab12003-in-metastatic-castration-resistant-prostate-cancer-mcrpc-has-met-its-predefined-primary-endpoint-paris-stock-exchange-a/#respond Thu, 29 Apr 2021 17:05:16 +0000 PRESS RELEASE PHASE 2B / 3 STUDY ASSESSMENT OF MASITINIB IN IN CASTRA-RESISTANT METASTATIC PROSTATE CANCER (MCRPC) HAS MET ITS PRIMARY ENDPOINT Paris, 29 April 2021, 7pm THIS AB Science SA (Euronext – FR0010557264 – AB) today announced that its Phase 2B / 3 study of masitinib (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) eligible […]]]>

PRESS RELEASE

PHASE 2B / 3 STUDY ASSESSMENT OF MASITINIB IN IN CASTRA-RESISTANT METASTATIC PROSTATE CANCER (MCRPC) HAS MET ITS PRIMARY ENDPOINT

Paris, 29 April 2021, 7pm THIS

AB Science SA (Euronext – FR0010557264 – AB) today announced that its Phase 2B / 3 study of masitinib (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) eligible for chemotherapy has met its predefined primary endpoint .

Patents relating to the results of Study AB12003 are pending and detailed results of Study AB12003 will be presented in a webcast with key opinion leaders that will take place as soon as the patents are filed.

About study AB12003

Study AB12003 was an international, multicenter, randomized, double-blind, placebo-controlled, 2 parallel group, phase 3 study in chemotherapy-eligible metastatic castrate-resistant prostate cancer (mCRPC). The study aimed to compare the efficacy and safety of masitinib (6.0 mg / kg / day) in combination with docetaxel versus placebo in combination with docetaxel. Docetaxel has been combined with prednisone.

The primary endpoint of the study was progression-free survival (PFS).

The target patient population consisted of adult males who had progressed to develop metastatic castration-resistant prostate cancer (mCRPC) following castration treatment (i.e. reduction in androgen / testosterone / DHT available by chemical or surgical means) and were therefore eligible for chemotherapy.

About castration resistant prostate cancer (CRPC)

The development of prostate cancer is often caused by male sex hormones called androgens, including testosterone. Castrate-resistant prostate cancer (CRPC) is defined as the progression of the disease despite androgen depletion (hormone) therapy and may present as a continuous increase in serum levels of prostate specific antigen. prostate (PSA), the progression of a pre-existing disease and / or the appearance of new metastases. Metastatic CRPC (mCRPC) occurs when cancer spreads to other parts of the body.

Prostate cancer is the most common cause of cancer in men, with 137.9 new cases per 100,000 men per year [1]. The estimated prevalence of people with prostate cancer is 113 per 100,000 [2], with approximately 15% of patients with metastatic castration-resistant prostate cancer (mCRPC) eligible for chemotherapy [3]. For example, the population with metastatic castrate-resistant prostate cancer (mCRPC) eligible for chemotherapy is approximately 75,000 in the EU and 50,000 in the US.

Prostate cancer is also the second leading cause of cancer death in men, with the highest rates in North America, Australia, and northern and central Europe. Although the overall 5-year survival rate for prostate cancer is very high, up to 20% of men who undergo advanced treatment for prostate cancer will develop CRPC within 5 years, and at least 84% of them will have metastases. at the time of CRPC diagnosis [1]. Virtually all patients with metastatic disease become resistant to androgen deprivation therapy. Median survival of people with mCRPC ranges from around 15 to 36 months in recent studies, and 5-year survival is only 28% [1].

The references
[1] Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape of advanced prostate cancer. Urol Oncol. May 2017; 35S: S1-S13. doi: 10.1016 / j.urolonc.2017.01.020.
[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Global Incidence and Mortality for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018; 68 (6): 394–424.
[3] Scher 2015 – PLoSONE – symptomatic mCRPC that has not been treated or has not progressed on chemotherapy

About masitinib
Masitinib is a novel orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, cells important for immunity, by inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a variety of conditions in oncology, inflammatory diseases, and certain diseases of the central nervous system. In oncology, because of its immunotherapeutic effect, masitinib may have an effect on survival, alone or in combination with chemotherapy. By its activity on mast cells and microglia and therefore inhibiting the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKI), a class of targeted proteins whose action is essential in signaling pathways within cells. . Our programs only target diseases with high unmet medical needs, often fatal with short-term survival or rare or refractory to the previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the company’s principal compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine for oncology, neurological diseases and inflammatory diseases. The company is headquartered in Paris, France, and is listed on Euronext Paris (symbol: AB).

Further information is available on the AB Science website:
www.ab-science.com.

Forward-looking statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on plans, objectives, intentions and expectations regarding financial results, events, operations, future services, development. of products and their potential or future performance.

These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” and other similar terms. Although AB Science believes that these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties which are difficult to predict and generally beyond the control of AB Science and which may involve the actual results and events differ materially from those expressed, implied or anticipated in the forward-looking information and statements. These risks and uncertainties include uncertainties related to the development of the Company’s products which may not be successful or to the marketing authorizations granted by the competent authorities or, more generally, any factor that may affect the marketing capacity of the products developed by the Company. AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in chapter 4 “Risk factors” of the AB Science reference document filed with of the AMF on November 22, 2016, under number R. 16-078. AB Science disclaims any obligation or commitment to update forward-looking information and statements, subject to applicable regulations, in particular Articles 223-1 and following. of the AMF general regulations.

For more information, please contact:

AB Science
Financial communication and media relations
investors@ab-science.com

Media Relations – United States

RooneyPartners
Jeffrey Freedman
jfreedman@rooneyco.com

+1 646 432 0191

Media relations – France

NewCap
Arthur Rusty
arouille@newcap.fr

+33 (0) 1 44 71 00 15

Source link

]]>
https://annonce-fr.com/ab-science-announced-today-that-its-phase-2b-3-study-of-masitinib-ab12003-in-metastatic-castration-resistant-prostate-cancer-mcrpc-has-met-its-predefined-primary-endpoint-paris-stock-exchange-a/feed/ 0
Betclic adds Top 14 sponsorship to its domestic market functions https://annonce-fr.com/betclic-adds-top-14-sponsorship-to-its-domestic-market-functions/ https://annonce-fr.com/betclic-adds-top-14-sponsorship-to-its-domestic-market-functions/#respond Thu, 29 Apr 2021 10:11:57 +0000 https://annonce-fr.com/betclic-adds-top-14-sponsorship-to-its-domestic-market-functions/ Betclic Group continues its sponsorship campaign in the domestic market, announcing that it will become the official sports betting partner of the French Rugby Union. Top 14 league. Yesterday, France National Rugby League (LNR), the governing body of the Top 14, announced that Betclic has secured a three-season deal to become the league’s main sports […]]]>


Betclic Group continues its sponsorship campaign in the domestic market, announcing that it will become the official sports betting partner of the French Rugby Union. Top 14 league.

Yesterday, France National Rugby League (LNR), the governing body of the Top 14, announced that Betclic has secured a three-season deal to become the league’s main sports betting partner.

The deal will see Betclic join Orange, Land Rover, Tissot and Societe Generale as main sponsors of the Top 14, the highest professional level of the French rugby federation.

The partnership will also see Betclic become the “official statistics partner” of the Top 14, providing analysis, information and match day data to the top 14 broadcasters.

In addition, Betclic Marketing will develop a comprehensive marketing strategy to promote new Top 14 experiences and further promote NRL grassroots rugby initiatives.

Betclic revealed that it has started work on redesigning its sports betting offering for the top 14 markets, with the French bookmaker planning to broadcast all league matches on its betting platform.

From next September, Betclic will maintain the highest sponsorship profile of French betting, as an official partner of Top 14 Rugby, while continuing its functions as a high-level sports betting partner of Ligue 1 football.





Source link

]]>
https://annonce-fr.com/betclic-adds-top-14-sponsorship-to-its-domestic-market-functions/feed/ 0
Total: First quarter 2021 results -5- https://annonce-fr.com/total-first-quarter-2021-results-5/ https://annonce-fr.com/total-first-quarter-2021-results-5/#respond Thu, 29 Apr 2021 10:10:00 +0000 https://annonce-fr.com/total-first-quarter-2021-results-5/ to 2025 (GW) Onshore Offshore Onshore Offshore (1,2) Solar Wind Wind Other Total Solar Wind Wind Other Total France 3.2 1.0 0.0 0.0 4.2 3.5 1.0 0.0 0.1 4.6 Rest of Europe 5.2 0.3 0.4 0.0 5.9 5.1 0.3 0.4 0.0 5.7 Africa 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.2 Middle East […]]]>


to 2025 (GW)          Onshore  Offshore                       Onshore  Offshore 
(1,2)          Solar  Wind     Wind      Other  Total  Solar  Wind     Wind      Other  Total 
France         3.2    1.0      0.0       0.0    4.2    3.5    1.0      0.0       0.1    4.6 
Rest of 
 Europe        5.2    0.3      0.4       0.0    5.9    5.1    0.3      0.4       0.0    5.7 
Africa         0.1    0.1      0.0       0.0    0.2    0.1    0.1      0.0       0.0    0.2 
Middle East    0.2    0.0      0.0       0.0    0.2    0.1    0.0      0.0       0.0    0.1 
North America  3.4    0.2      0.0       0.7    4.2    0.6    0.3      0.0       0.0    0.9 
South America  0.8    0.8      0.0       0.0    1.6    0.5    0.3      0.0       0.0    0.9 
India          6.2    0.1      0.0       0.0    6.2    1.6    0.0      0.0       0.0    1.6 
Asia-Pacific   0.8    0.0      0.0       0.0    0.8    0.9    0.0      0.0       0.0    0.9 
Total          19.8   2.5      0.4       0.7    23.3   12.5   2.0      0.4       0.1    15.0 
 

(1) Includes 20% of the gross capacity of Adani Green Energy Ltd from the first quarter of 2021.

 

(2) End of period data.

 
             In operation           In construction                  In development 
Gross 
renewables 
capacity 
covered by 
PPA at 31 
March 2021          Onshore                Onshore  Offshore                Onshore  Offshore 
(GW)         Solar  Wind     Total  Solar  Wind     Wind      Total  Solar  Wind     Wind      Total 
Europe       0.6    1.3      1.9    0.3    0.3      0.8       1.4    3.8    0.3      X         4.2 
Asia         4.4    X        4.5    2.2    0.4      -         2.6    4.0    X        -         4.0 
North 
 America     0.8    X        0.8    X      X        -         0.2    0.3    X        -         0.3 
Rest of 
 World       0.3    X        0.5    X      X        -         0.4    0.2    X        -         0.3 
total        6.0    1.5      7.6    2.8    0.9      0.8       4.5    8.3    0.6      X         8.9 
 
 
          In operation           In construction                  In development 
PPA 
average 
price at 
31 march 
2021             Onshore                Onshore  Offshore                Onshore  Offshore 
($/MWh)   Solar  Wind     Total  Solar  Wind     Wind      Total  Solar  Wind     Wind      Total 
Europe    242    123      159    68     94       61        68     44     72       X         49 
Asia      88     X        87     46     49       -         47     40     X        -         40 
North 
 America  156    X        159    X      X        -         57     32     X        -         54 
Rest of 
 World    105    X        105    X      X        -         45     89     X        -         123 
total     113    115      113    48     66       61        55     42     87       X         46 
 

Adjustments to net income (Group share)

 
In millions of dollars                             1Q21   4Q20   1Q20     1Q19 
Special items affecting net income (Group share)   (342)  (683)  (334)    (14) 
Gain (loss) on asset sales                         -      104    -        - 
Restructuring charges                              (161)  (194)  (80)     (2) 
Impairments                                        (144)  (71)   -        - 
Other                                              (37)   (522)  (254)    (12) 
After-tax inventory effect : FIFO vs. replacement 
 cost                                              689    224    (1,414)  388 
Effect of changes in fair value                    (6)    46     1        (22) 
 
Total adjustments affecting net income             341    (413)  (1,747)  352 
 

Investments – Divestments

 
                                                           1Q21          1Q21 
                                                            vs            vs 
In millions of dollars                1Q21   4Q20   1Q20    1Q20  1Q19    1Q19 
Organic investments ( a )             2,379  3,432  2,523  -6%    2,784  -15% 
capitalized exploration               243    214    135    +80%   232    +5% 
increase in non-current loans         292    355    279    +5%    130    x2,2 
repayment of non-current loans, 
 excluding organic loan repayment 
 from equity affiliates               (96)   (212)  (117)  ns     (134)  ns 
change in debt from renewable 
 projects (Group share)               (167)  (46)   (105)  ns     -      ns 
Acquisitions ( b )                    2,208  1,538  1,644  +34%   669    x3,3 
Asset sales ( c )                     618    439    542    +14%   363    +70% 
change in debt from renewable 
 projects (partner share)             100    15     61     64%    -      ns 
Other transactions with 
non-controlling interests ( d )       -      -      -      ns     -      ns 
Net investments ( a + b - c - d )     3,969  4,531  3,625  +9%    3,090  +28% 
Organic loan repayment from equity 
 affiliates ( e )                     (30)   (77)   7      ns     -      ns 
Change in debt from renewable 
 projects financing * ( f )           267    61     166    +61%   -      ns 
Capex linked to capitalized leasing 
 contracts ( g )                      22     39     24     -8%    -      ns 
Cash flow used in investing 
 activities ( a + b - c + e + f -g)   4,184  4,476  3,774  +11%   3,090  +35% 
 

* Change in debt for renewable projects (Group share and partner share)

 

Cash flow

 
                                                         1Q21            1Q21 
                                                          vs              vs 
In millions of dollars            1Q21   4Q20   1Q20      1Q20  1Q19      1Q19 
Operating cash flow before 
 working capital changes w/o 
 financials charges (DACF)        5,750  4,933  4,277    +34%   6,277    -8% 
Financial charges                 (384)  (436)  (512)    ns     (503)    ns 
Operating cash flow before 
 working capital changes ( a ) 
 *                                5,366  4,498  3,765    +43%   5,774    -7% 
(Increase) decrease in working 
 capital **                       (555)  976    (633)    ns     (2,711)  ns 
Inventory effect                  883    308    (1,796)  ns     566      +56% 
capital gain from renewable 
 projects sale                    (66)   (32)   (44)     ns     -        ns 
Organic loan repayment from 
 equity affiliates                (30)   (77)   7        ns     -        ns 
Cash flow from operations         5,598  5,674  1,299    x4,3   3,629    +54% 
 
Organic investments ( b )         2,379  3,432  2,523    -6%    2,784    -15% 
Free cash flow after organic 
 investments, w/o net asset 
 sales ( a - b )                  2,987  1,066  1,242    x2,4   3,249    -8% 
 
Net investments ( c )             3,969  4,531  3,625    +9%    3,090    +28% 
Net cash flow ( a - c )           1,397  (33)   140      x10    2,943    -53% 
 

* Operating cash flow before change in working capital is defined as the cash flow from operating activities before changes in working capital at replacement cost, excluding the valuation effect of iGRP contracts and including the surplus. value on the sale of renewable projects (from the first quarter of 2020).

Historical data has been restated to cancel the impact of the fair valuation of contracts in the iGRP sector.

 

** Changes in working capital requirements are presented excluding the valuation effect of iGRP contracts.

 

Gear ratio

 
In millions of dollars          03/31/2021  31/12/2020  03/31/2020  03/31/2019 
Current borrowings *            19,279      15,893      17,361      12,998 
Other current financial 
 liabilities                    351         203         604         651 
Current financial assets *      (4,492)     (4,519)     (6,870)     (3,373) 
Net financial assets 
 classified as held for sale    -           313         -           227 
Non-current financial debt *    44,842      52,467      42,461      38,264 
Non-current financial assets *  (2,669)     (3,762)     (993)       (587) 
Cash and cash equivalents       (30,285)    (31,268)    (21,634)    (25,432) 
Net debt (a)                    27,026      29,327      30,929      22,748 
 
Shareholders' equity - Group 
 share                          109,295     103,702     112,006     117,993 
Non-controlling interests       2,390       2,383       2,428       2,365 
Shareholders' equity (b)        111,685     106,085     114,434     120,358 
 
Net-debt-to-capital ratio = a 
 / (a+b)                        19.5%       21.7%       21.3%       15.9% 
 
Leases (c)                      7,747       7,812       7,309       6,991 
Net-debt-to-capital ratio 
 including leases (a+c) / 
 (a+b+c)                        23.7%       25.9%       25.0%       19.8% 
 

* Excludes rental receivables and rental debts.

 

Return on average capital employed

 

> Twelve months ended March 31, 2021

 
              Integrated 
              Gas,         Exploration 
In millions   Renewables   &             Refining &    Marketing & 
of dollars    & Power      Production    Chemicals     Services      Group 
Adjusted net 
 operating 
 income       1,850        3,635         900           1,206         6,915 
Capital 
 employed at 
 03/31/2020*  44,236       85,622        12,878        8,764         152,374 
Capital 
 employed at 
 03/31/2021*  48,423       78,170        10,403        8,198         145,180 
ROACE         4.0%         4.4%          7.7%          14.2%         4.6% 
 

> Twelve months ended December 31, 2020

 
              Integrated 
              Gas,         Exploration 
In millions   Renewables   &             Refining &    Marketing & 
of dollars    & Power      Production    Chemicals     Services      Group 
Adjusted net 
 operating 
 income       1,778        2,363         1,039         1,224         5,806 
Capital 
 employed at 
 12/31/2019*  41,549       88,844        12,228        8,371         148,828 
Capital 
 employed at 
 12/31/2020*  45,611       78,928        11,375        8,793         142,617 
ROACE         4.1%         2.8%          8.8%          14.3%         4.0% 
 

(MORE FOLLOWING) Dow Jones Newswires

April 29, 2021 6:10 a.m. ET (10:10 a.m. GMT)



Source link

]]>
https://annonce-fr.com/total-first-quarter-2021-results-5/feed/ 0
Global Eosinophilic Esophagitis Market to 2030 – Market Overview, Epidemiology and Forecast – ResearchAndMarkets.com https://annonce-fr.com/global-eosinophilic-esophagitis-market-to-2030-market-overview-epidemiology-and-forecast-researchandmarkets-com/ https://annonce-fr.com/global-eosinophilic-esophagitis-market-to-2030-market-overview-epidemiology-and-forecast-researchandmarkets-com/#respond Thu, 29 Apr 2021 09:22:00 +0000 https://annonce-fr.com/global-eosinophilic-esophagitis-market-to-2030-market-overview-epidemiology-and-forecast-researchandmarkets-com/ DUBLIN – (BUSINESS WIRE)–The “Eosinophilic Esophagitis – Market Overview, Epidemiology, and Market Forecast – 2030” drug pipelines have been added to ResearchAndMarkets.com from offer. This report provides an in-depth understanding of historical and predicted epidemiology as well as EoE market trends in US, EU5 (Germany, Spain, Italy, France and UK) and Japan. The EoE market […]]]>


DUBLIN – (BUSINESS WIRE)–The “Eosinophilic Esophagitis – Market Overview, Epidemiology, and Market Forecast – 2030” drug pipelines have been added to ResearchAndMarkets.com from offer.

This report provides an in-depth understanding of historical and predicted epidemiology as well as EoE market trends in US, EU5 (Germany, Spain, Italy, France and UK) and Japan.

The EoE market report provides current treatment practices, emerging drugs, individual therapies market share, current and forecast EoE market size from 2018 to 2030, segmented by seven major markets. The report also covers the current EoE treatment practice / algorithm, market drivers, market barriers, and unmet medical needs to manage best opportunities and assess the potential of the underlying market.

Main conclusions

The disease epidemiology covered in the report provides historical and predicted epidemiology of segmented eosinophilic esophagitis such as diagnosed prevalent cases of eosinophilic esophagitis, gender-specific eosinophilic esophagitis cases and esophagitis cases. age-specific eosinophils. the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain and United Kingdom) and Japan from 2018 to 2030.

KOL Views

To keep up with current market trends, we consider the opinions of KOLs and SMEs working in the field of eosinophilic esophagitis through primary research to fill data gaps and validate our secondary research. Their advice helps to understand and validate current and emerging therapy treatment models or Eosinophilic Esophagitis market trend. This will help clients in upcoming potential new treatment by identifying the overall market scenario and unmet need.

Competitive intelligence analysis

The publisher performs competitive and business intelligence analysis of the eosinophilic esophagitis market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG matrix, market entry strategies, etc. . The inclusion of the analysis is entirely dependent on the availability of data.

Scope of the report

  • The report covers the descriptive overview of EoE, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.

  • A comprehensive overview was provided on the epidemiology and treatment of eosinophilic esophagitis in 7MM

  • In addition, a comprehensive account of current and emerging therapies for eosinophilic esophagitis is provided, as well as the assessment of new therapies, which will impact the current treatment landscape.

  • A detailed review of the Eosinophilic Esophagitis market; historical and planned, is included in the report, covering drug awareness in the 7MM

  • The report provides an advantage while developing business strategies by understanding the trends shaping and driving the global Eosinophilic Esophagitis market

Highlights of the report

  • In the coming years, the Eosinophilic Esophagitis market is set to change due to the growing awareness of the disease and additional healthcare spending across the world; which would expand the market size to allow drug manufacturers to further penetrate the market

  • Businesses and academics are working to assess challenges and research opportunities that could influence R&D in eosinophilic esophagitis. Therapies under development focus on new approaches to treat / improve disease condition

  • The main players are involved in the development of therapies for EoE. The launch of emerging therapies will have a significant impact on the EoE market

  • A better understanding of the pathogenesis of the disease will also contribute to the development of new therapies for EOE.

In-depth analysis of pipeline assets at different stages of development (phase III and phase II), different emerging trends and benchmarking of products in pipeline with detailed clinical profiles, major cross competitors, launch date as well that product development activities support clients in making decisions about their therapeutic portfolio by identifying the global scenario of research and development activities

Outlook for the Eosinophilic Esophagitis Report

  • Patient population

  • Therapeutic approaches

  • Eosinophilic esophagitis pipeline analysis

  • Eosinophilic Esophagitis Market Size and Trends

  • Market opportunities

  • Impact of future therapies

Eosinophilic Esophagitis Report Key Highlights

  • 10-year forecast

  • Coverage 7MM

  • Segmentation of the epidemiology of eosinophilic esophagitis

  • Key Competitors

  • Highly analyzed market

  • Absorption of drugs

Evaluation of the Eosinophilic Esophagitis Report

  • Current treatment practices

  • Unmet needs

  • Pipeline Product Profiles

  • Market attractiveness

  • Market factors and obstacles

Reasons to buy

  • The report will help develop business strategies by understanding the trends shaping and driving the Eosinophilic Esophagitis market

  • To understand the future market competition in the Eosinophilic Esophagitis market and an in-depth look at the major market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for eosinophilic esophagitis in the United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

  • Identifying strong future market players will help design strategies that will help get ahead of the competition.

  • To organize sales and marketing efforts by identifying the best opportunities for the Eosinophilic Esophagitis market.

  • To understand the future market competition in the Eosinophilic Esophagitis market.

Companies mentioned

  • Allakos

  • Arena Pharmaceutical

  • AstraZeneca

  • Bristol-Myers Squibb

  • Dr Falk Pharma GmbH

  • Ellodi Pharmaceuticals

  • EsoCap AG

  • GlaxoSmithKline

  • Regeneron Pharmaceuticals / Sanofi

  • Takeda

For more information on this Drug Pipeline Report, visit https://www.researchandmarkets.com/r/77kucn



Source link

]]>
https://annonce-fr.com/global-eosinophilic-esophagitis-market-to-2030-market-overview-epidemiology-and-forecast-researchandmarkets-com/feed/ 0
Auto market a ‘substantial opportunity’ for post-covid Lemonade – GlobalData | Latest news https://annonce-fr.com/auto-market-a-substantial-opportunity-for-post-covid-lemonade-globaldata-latest-news/ https://annonce-fr.com/auto-market-a-substantial-opportunity-for-post-covid-lemonade-globaldata-latest-news/#respond Thu, 29 Apr 2021 07:39:15 +0000 https://annonce-fr.com/auto-market-a-substantial-opportunity-for-post-covid-lemonade-globaldata-latest-news/ Lemonade has a “substantial opportunity” to capitalize on the auto insurance market after the pandemic, according to data and analysis firm GlobalData. GlobalData citing the U.S. auto market worth $ 35,815 million in gross written premium (GWP) in 2020, the insurtech model – which is designed to be both digital and value-driven – is well […]]]>


Lemonade has a “substantial opportunity” to capitalize on the auto insurance market after the pandemic, according to data and analysis firm GlobalData.

GlobalData citing the U.S. auto market worth $ 35,815 million in gross written premium (GWP) in 2020, the insurtech model – which is designed to be both digital and value-driven – is well suited to capitalize on this opportunity.

Ben Carey-Evans, Insurance Analyst at GlobalData, said: “The US market is relatively competitive for digital and telematics auto insurance. In recent years, companies such as Root and Metromile have received huge funding in this area, making them both insurtech unicorns. “

This follows Lemonade’s announcement earlier this month that it is entering the auto insurance market.

Upsell opportunity

Meanwhile, GlobalData UK Insurance Consumer Survey found that a more flexible and digital auto insurance policy, like the one Lemonade is likely to offer, could be even more relevant in the wake of the Covid-19 pandemic.

It found that more than two-thirds (69.4%) of respondents said they would drive fewer kilometers per year due to the pandemic.

Therefore, consumers could benefit from pay-per-mile insurance policies offered by By Miles and Metromile, as value and flexibility will become essential.

Carey-Evans added, “Lemonade will bring to the market a wide range of digital expertise and very strong customer service skills.

“The launch of Lemonade Car is [its] early stages and while it hasn’t released many details yet, it has promised to deliver instant claims and value, while also focusing on EVs.

“This looks like a great upselling opportunity for Lemonade, a company that primarily sells fast, digital home policies to their clients.”

Brand awareness is essential

The consumer survey also found that only 7% of UK consumers had heard of lemonade. This is not a problem at the moment as the company is launching in the United States, but it has made clear its intentions to locate in Europe over the past two years, with insurtech selling home insurance in Germany, France and the Netherlands.

Brand awareness will be essential as insurtech seeks to challenge established market players. However, strong support makes him a hurdle he can overcome with marketing, as his digital expertise is expected to prove popular, GlobalData noted.



Source link

]]>
https://annonce-fr.com/auto-market-a-substantial-opportunity-for-post-covid-lemonade-globaldata-latest-news/feed/ 0
Advicenne publishes its annual financial results as of December 31, 2020 and confirms its 2021 outlook https://annonce-fr.com/advicenne-publishes-its-annual-financial-results-as-of-december-31-2020-and-confirms-its-2021-outlook/ https://annonce-fr.com/advicenne-publishes-its-annual-financial-results-as-of-december-31-2020-and-confirms-its-2021-outlook/#respond Wed, 28 Apr 2021 21:30:00 +0000 https://annonce-fr.com/advicenne-publishes-its-annual-financial-results-as-of-december-31-2020-and-confirms-its-2021-outlook/ PARIS–(BUSINESS WIRE) – Regulatory news: Advicenne (Paris: ADVIC) (BSE: ADVIC) (Euronext: ADVIC), a French company specializing in the development of therapeutic products suitable for children and adults for the treatment of orphan nephrological and neurological diseases, today publishes its 2020 financial results . 2020 HIGHLIGHTS Scientific developments On March 10, 2020, Advicenne was authorized to […]]]>


PARIS–(BUSINESS WIRE) – Regulatory news:

Advicenne (Paris: ADVIC) (BSE: ADVIC) (Euronext: ADVIC), a French company specializing in the development of therapeutic products suitable for children and adults for the treatment of orphan nephrological and neurological diseases, today publishes its 2020 financial results .

2020 HIGHLIGHTS

Scientific developments

On March 10, 2020, Advicenne was authorized to make ADV7103 available as part of a Temporary Authorization for Use (TAU) scheme set up by the National Agency for the Safety of Medicine and Health Products (National Agency for the Safety of Medicines and Health Products (ANSM)). This authorization allows the exceptional use of coated granules of 8 mEq and 24 mEq in sachets for the treatment of distal renal tubular acidosis (dRTA) in France. Its prescription is reserved for doctors specializing in nephrology.

On December 10, 2020, Advicenne received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending the approval of ADV7103 (Sibnayal®) as a treatment for renal tubular acidosis distal (dRTA) in Europe.

Legal developments

In May 2020, the Company created a subsidiary in the United States to manage its activity, in particular the clinical activity. Advicenne Inc. has started recruiting a team of US specialists to deploy the Company’s activities in this key market.

In addition, the governance of the company has evolved; following the separation of the functions of CEO and Chairman of the Board of Directors at the end of 2019, Dr André Ulmann was appointed Interim CEO on March 12, 2020, replacing Dr Luc-André Granier. Ms. Hege Hellstrom was appointed independent director at the general meeting of May 26, 2020.

Financial developments

As part of its financing agreement of 20 million euros with the European Investment Bank (EIB), Advicenne strengthened its financial structure by drawing a first tranche of 7.5 million euros; this tranche provides for a one-off repayment over 5 years.

The Company also obtained 4.3 million euros in additional financing within the framework of two loans guaranteed by the State for a maximum duration of 6 years.

EVENT SINCE END 2020

On February 15, 2021, Peter Meeus assumed the role of CEO of the Company, ending Dr. André Ulmann’s tenure as interim CEO.

OUTLOOK 2021

As specified in its press release of March 25, 2021, the Company expects European marketing approval for ADV7013 (Sibnayal®) by the end of the second quarter of 2021. It is currently in discussions with several partners regarding the commercialization. of this product in Europe during this fiscal year.

The clinical development of Sibnayal®, suspended due to the pandemic, continues with the resumption of the pivotal phase III trial of dRTA in the United States and the finalization of the protocols in the orphan indication of cystinuria in Europe and the United States -United.

KEY FINANCIAL DATA AT DECEMBER 31, 2020

The main financial data for fiscal year 2020 are presented in the table below: they are taken from the financial statements prepared in accordance with IFRS standards, as approved by the Board of Directors at its meeting of April 28, 2021. full financial statements will be available on the Company’s website: www.advicenne.com.

INCOME STATEMENT (in thousands of euros)

December 31, 2020

December 31, 2019

Returned

2,062

1,663

Other exploitation products

1,503

921

Total income and other income

3,564

2,584

Functionnary costs

-17,700

-16 832

Operating loss

-14,136

-14,248

Net loss

-14 846

-14,198

Loss per share (€ / share)

-1.76

-1.74

Diluted loss per share (€ / share)

-1.76

-1.74

2020 revenue increased by 25% compared to 2019. Sales for 2020 were mainly driven by Likozam® and Levidcen®, two licensed products for the treatment of epilepsy. Advicenne marketed these drugs in response to requests from hospital doctors for an alternative treatment for children with this disease.

Sales of the Company’s flagship drug candidate, ADV7103, under the European early access programs (EAP) or the Temporary Authorization for Use (TAU), totaled € 0.8 million in 2020, up by 60% (€ 0.3 million) compared to 2019.

The increase in operating costs in 2020 is mainly attributable to overhead costs.

Advicenne thus recorded a net loss of 14.8 million euros in 2020.

BALANCE SHEET (in thousands of euros)

December 31, 2020

December 31, 2019

Non-current assets

3 215

2 241

Current assets

20 789

21 638

of which cash and cash equivalents

16,771

16 629

Total assets

24,004

23 879

Total equity

3 272

16,720

Non-current liabilities

9 366

1,536

of which borrowings and financial debts

9,247

1,324

Current liabilities

11 366

5 623

of which borrowings and financial debts

4,550

288

of which trade payables

4,434

3,907

of which other current liabilities

2 383

1427

Total responsibilities

24,004

23 879

At the end of December 2020, the Company’s cash and cash equivalents were stable at 16.8 million euros. The financial debt takes into account the loan obtained from the European Investment Bank and loans guaranteed by the State for a total amount of 12 million euros.

CASH FLOWS (in thousands of euros)

December 31, 2020

December 31, 2019

Operating cash flow

-11,694

-9,475

of which cash flow

-13,592

-13,303

of which change in working capital requirement

1,898

3 828

Cash flow from investing activities

-694

-1 112

Cash flow from financing activities

12,529

983

of which change in loans and repayable advances

12,121

276

Cash change

142

-9,603

Cash opening

16 629

26 232

Closing liquidation

16,771

16 629

In 2020, cash flow from operating activities was negative at 11.7 million euros, due to the operating loss, partially offset by a positive impact of the working capital requirement.

Cash flow from investing activity mainly related to improvements to the ADV7103 packaging line in anticipation of the commercial launch of this product.

These flows were offset by a positive cash flow of 12.5 million euros from the financing activity, which includes the issue of bonds and a capital increase of 0.7 million euros continued upon the exercise of warrants.

The Company estimates that its current resources will enable it to finance its operations planned until October 2021, on the basis of the facts and assumptions detailed in note 4.3 “Business continuity” to the 2020 consolidated financial statements of the Company prepared. in accordance with IFRS. The Company is actively studying each option with a view to obtaining additional short-term financial resources.

The audit procedures have been completed and the auditor’s certification report is pending. It will include a note on significant uncertainties related to going concern beyond October 2021.

ABOUT ADVICENNE

Advicenne (Euronext: ADVIC) is a pharmaceutical company founded in 2007, specializing in the development of innovative treatments in nephrology. Its main drug candidate is currently in advanced clinical trials for two kidney diseases: renal tubular acidosis and cystinuria. ADV7103 recently received a positive opinion from the CHMP for the treatment of dRTA.

Based in Paris, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was listed on the Euronext Brussels stock exchange in 2019.

For more information see: www.advicenne.com

Forward-looking statements

This press release contains certain forward-looking statements relating to Advicenna’s business, which should not be construed in themselves as historical facts. These statements include projections and estimates, as well as the assumptions on which they are based, as well as observations relating to operations, projects in progress, objectives, product development and their future performance and expectations regarding the future. financial results.

In some cases, forward-looking statements may be identified by words such as “may”, “should”, “may”, “expects”, “anticipates”, “believes”, “intends”, “believes”. “,” Aims, “” targets “or similar words. Although the management of Advicenna believes that these forward-looking statements are reasonably worded, investors should be aware that they are subject to a number of risks and uncertainties known and unknown and to other factors that could cause actual results, performance or achievements to differ materially. any future results, performance or achievements expressed or implied by these forward-looking statements. In particular, expectations Advicenne could be affected, among other things, by uncertainties related to the marketing and marketing of Advicenne products or by any other risks and uncertainties developed or identified in any public document concerning submitted by Advicenne to the French Financial Markets Authority (Financial Markets Authority (AMF)), including those listed in Chapter 4 “Risk factors” of its universal registration document, filed with the latter on December 22, 2020. Notwithstanding compliance with article 223-1 of the general regulations of the AMF (the information disclosed must be “accurate, precise and fairly presented”), Advicenne disclaims any intention or obligation to update or publicly revise any forward-looking statement, whether as a result of new information, future events or otherwise.



Source link

]]>
https://annonce-fr.com/advicenne-publishes-its-annual-financial-results-as-of-december-31-2020-and-confirms-its-2021-outlook/feed/ 0
Global Integrated Facilities Management Market Expected To Grow From USD 84.65 Billion In 2020 To USD 114.86 Billion By 2026 https://annonce-fr.com/global-integrated-facilities-management-market-expected-to-grow-from-usd-84-65-billion-in-2020-to-usd-114-86-billion-by-2026/ https://annonce-fr.com/global-integrated-facilities-management-market-expected-to-grow-from-usd-84-65-billion-in-2020-to-usd-114-86-billion-by-2026/#respond Wed, 28 Apr 2021 11:09:48 +0000 https://annonce-fr.com/global-integrated-facilities-management-market-expected-to-grow-from-usd-84-65-billion-in-2020-to-usd-114-86-billion-by-2026/ New York, April 28, 2021 (GLOBE NEWSWIRE) – Reportlinker.com Announces the Release of “Global Integrated Facilities Management Market, By Type, By Service, By Solution, By End User, By Region, Competition, Forecast and Opportunities , 2026 “- https://www.reportlinker.com/p05757896/?utm_source=GNW The global integrated facilities management market can be segmented into type, services, IT (information technology) support, solution, end […]]]>

New York, April 28, 2021 (GLOBE NEWSWIRE) – Reportlinker.com Announces the Release of “Global Integrated Facilities Management Market, By Type, By Service, By Solution, By End User, By Region, Competition, Forecast and Opportunities , 2026 “- https://www.reportlinker.com/p05757896/?utm_source=GNW

The global integrated facilities management market can be segmented into type, services, IT (information technology) support, solution, end user, and region.On the basis of type, the market can be segmented into hard service and service software, where hard service segment held a market share of around 55% in 2020 due to increased investment in energy and project management to achieve long-term efficiency.

Additionally, new office buildings in emerging economies are expected to drive the market during the forecast period.

On the basis of service, the market is segmented into property and property management, cleaning and hygiene, security and staffing, IT support and others, among which the market share of property and property management segment was around 26 % in 2020.

Integrated facilities management in the property and property management industry includes services that include construction management, marketing, building engineering, accounting, and financial services to owners and investors in offices, industrial and commercial properties. The growing development of a sustainable infrastructure and the growing presence of many companies to adopt a changing organizational structure and work management are the main drivers of the global integrated facilities management market.

The largest contributor to the global integrated facilities management market was North America with around 44% value share in 2020; the United States was the largest contributing country in the region with around 83% share in 2020 , followed by Canada and Mexico.

In addition, the demand for outsourced facilities management services is increasing in developing countries due to growing awareness and improving economies.

The major players in the global integrated facilities management market are JLL Inc (Jones Lang LaSalle IP, Inc), ISS A / S (International Service System), CBRE Group Inc, Cushman & Wakefield plc, Sodexo Inc., Compass Inc. , Aramark Corporation, Coor Service Management Holding AB, Mitie Group PLC, MacLellan Integrated Services, Inc. Market players are continually presenting services with real-time response, 24/7 connectivity and availability, in order to build a customer base.

Years considered for this report:

Historical years: 2016-2019
Base year: 2020
Estimated year: 2021
Forecast period: 2022-2026

Goal of the study:

• The main objective of the study is to understand and obtain insights into the global Integrated Facilities Management market by value and its segmental analysis by type, by service, by IT support, by solution, by end user. , by region and by company.
• To analyze the historical growth in market size of the global Integrated Facilities Management market from 2016 to 2020.
• To estimate and forecast the market size of the global Integrated Facilities Management market from 2021 to 2026 and the growth rate to 2026.
• Classify and forecast the global integrated facilities management market by type – hardware service and software service.
• Rank and forecast the global integrated facilities management market by department – building and asset management, cleaning and hygiene, security and staffing, IT support and others.
• Rank and forecast the global integrated facility management market by solution – asset and space management, project management and real estate portfolio management and lease administration, energy and environmental sustainability management, maintenance management and others
• Rank and forecast the global integrated facilities management market by end user (BFSI, utilities, aerospace and defense, telecommunications, manufacturing, supply chain and logistics, real estate and infrastructure, healthcare, retail and others. ).
• To classify and forecast the global integrated facilities management market by regions such as North America, Asia-Pacific, Europe, Middle East & Africa, and South America.
• Identify key drivers and challenges for the global integrated facilities management market.
• Identify the main trends in the global integrated facilities management market.
• To present the profile of the major companies operating in the global integrated facilities management market.
To analyze and forecast the global Integrated Facilities Management market, top-down and bottom-up approaches have been used, several employees of major companies were interviewed through telephone conversations to extract and verify the information collected at the source.

Also, a brief study of major players operating in the global Integrated Facilities Management market has also been undertaken, besides, a detailed and in-depth review of the information has been done to understand each and every external or internal policy and factor that might increase or decrease the application for integrated facility. Management, overall.

To extract the data, primary surveys were conducted among the main industry players and stakeholders. The future plans of the main actors have been studied and the projects commissioned in the country have been identified.
Various secondary sources such as white papers and secondary literature on Integrated Facilities Management, Annual Reports, Investor Presentation, International Monetary Fund and World Bank were also investigated by the analyst.

Key target audience:

• Providers of integrated facilities management services.
• Integrated facilities management services to customers, departments and users.
• Organizations, forums and alliances related to the global integrated facilities management market.
• Government bodies such as regulators and policy makers.
• Market research and consulting companies
The study is essential for providing useful information to industry stakeholders such as facility service providers, managers, vendors, lenders, and end users related to the Integrated Facility Management Market. The report also provides useful information on the market segments to target over the next few years in order to develop investment strategies and capitalize on growth opportunities in specific market segments and geographies.

Scope of the report:

In this report, the Global Integrated Facilities Management Market has been segmented into following categories in addition to industry trends which have also been listed below:
• Global Integrated Facilities Management Market, By Type:
o Hard service
o Gentle service
• Global Integrated Facilities Management Market, by Service:
o Building and property management
o Cleaning and hygiene
o Security and staffing
o IT assistance
On the site
Cloud
o Others
• Global Integrated Facilities Management Market, By Solution
o Asset and space management
o Project management and real estate portfolio management and lease administration
o Management of energy and environmental sustainability
o Maintenance management
o Others
• Global Integrated Facilities Management Market, By End User:
o BFSI
o Utilities
o Aerospace and defense
o Telecommunications
o Manufacturing
o Supply chain and logistics
o Real estate and infrastructure
o Health
o Retail
o Others
• Global Integrated Facilities Management Market, By Region:
o North America
United States
Canada
Mexico
o Asia-Pacific
China
India
South Korea
Australia
Singapore
Malaysia
o Europe
France
Germany
UK
Italy
Russia
o Middle East and Africa
South Africa
Saudi Arabia
United Arab Emirates
Egypt
o South America
Brazil
Argentina
Chile

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global Integrated Facilities Management market.

Customizations available:

With the given market data, we offer customizations based on the specific needs of a business. The following customization options are available for the report:

Company Info

• Detailed analysis and profiling of other market players (up to five).
Read the full report: https://www.reportlinker.com/p05757896/?utm_source=GNW

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


Source link

]]>
https://annonce-fr.com/global-integrated-facilities-management-market-expected-to-grow-from-usd-84-65-billion-in-2020-to-usd-114-86-billion-by-2026/feed/ 0
MSC set to continue to dominate the European market – Cruise Industry News https://annonce-fr.com/msc-set-to-continue-to-dominate-the-european-market-cruise-industry-news/ https://annonce-fr.com/msc-set-to-continue-to-dominate-the-european-market-cruise-industry-news/#respond Wed, 28 Apr 2021 10:45:09 +0000 https://annonce-fr.com/msc-set-to-continue-to-dominate-the-european-market-cruise-industry-news/ As Europe prepares for aggressive market expansion over the next few years, for 2022, MSC Cruises will continue to lead the European market with 18 ships and an estimated annual passenger capacity of three million, according to the 2021 Cruise Industry News Annual Reportt. Its closest competitor will be Costa Cruises with 10 ships and […]]]>


As Europe prepares for aggressive market expansion over the next few years, for 2022, MSC Cruises will continue to lead the European market with 18 ships and an estimated annual passenger capacity of three million, according to the 2021 Cruise Industry News Annual Reportt.

Its closest competitor will be Costa Cruises with 10 ships and an estimated annual passenger capacity of 1.6 million.

MSC and Costa market their cruises across Europe, as do North American brands that dedicate ships to Europe during the summer months, while other major European cruise lines tend to be national brands, such as AIDA, TUI and Phoenix Reisen in Germany, and Cunard, Fred. Olsen, Marella and P&O in the UK market.

The other national brands in Spain and France have long since disappeared, with Ponant remaining the only French cruise line, although marketing in all major markets, including the United States.

Combined, Carnival Corporation’s European brands will be able to carry more than four million passengers in Europe in 2022, compared to three million for MSC and around one million for the TUI group, i.e. TUI Cruises, Marella and Hapag-Lloyd . However, by 2027, MSC is expected to catch up with Carnival Corporation in terms of market capacity based on companies’ new build orders and vessel deployment.

In total, the market capacity of the European brand is estimated at 9.2 million passengers in 2022 and 11.5 million in 2027.

AB InBev



Source link

]]>
https://annonce-fr.com/msc-set-to-continue-to-dominate-the-european-market-cruise-industry-news/feed/ 0
The industrial Ethernet market was valued at USD 9.2 billion in 2020 and is expected to reach USD 13.7 billion by 2026. It is expected to grow at a CAGR of 7.3% https://annonce-fr.com/the-industrial-ethernet-market-was-valued-at-usd-9-2-billion-in-2020-and-is-expected-to-reach-usd-13-7-billion-by-2026-it-is-expected-to-grow-at-a-cagr-of-7-3/ https://annonce-fr.com/the-industrial-ethernet-market-was-valued-at-usd-9-2-billion-in-2020-and-is-expected-to-reach-usd-13-7-billion-by-2026-it-is-expected-to-grow-at-a-cagr-of-7-3/#respond Wed, 28 Apr 2021 10:39:48 +0000 https://annonce-fr.com/the-industrial-ethernet-market-was-valued-at-usd-9-2-billion-in-2020-and-is-expected-to-reach-usd-13-7-billion-by-2026-it-is-expected-to-grow-at-a-cagr-of-7-3/ New York, April 28, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Industrial Ethernet Market with COVID-19 Impact Analysis by Offer, Protocol, End-Use Industry and Region – Global Forecast to 2026 “- https://www.reportlinker.com/p04412111/?utm_source=GNW Growing adoption of 5G to provide a growth opportunity for market players. Based on supply, hardware will account for […]]]>

New York, April 28, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Industrial Ethernet Market with COVID-19 Impact Analysis by Offer, Protocol, End-Use Industry and Region – Global Forecast to 2026 “- https://www.reportlinker.com/p04412111/?utm_source=GNW
Growing adoption of 5G to provide a growth opportunity for market players.

Based on supply, hardware will account for the largest share between 2021 and 2026.

The hardware segment is expected to hold the largest share of the industrial Ethernet market. Devices such as IP phones and PCs are connected to the Internet to enable fast communication in industries.

Machine-to-machine (M2M) communication in the industrial environment facilitates efficient plant operations, speeds up operations and ensures increased reliability and robustness in various industries, such as automotive, transportation, aerospace and defense, pharmaceuticals and agrifood.

However, a secure and robust network is necessary to protect devices connected to the Internet against manipulation or theft of data. Such a robust application specific network can be built using network components.

The hardware segment covers the components used to build specific communication networks. Components include switches, routers, gateways, power supplies, controllers, and more.

EtherCAT will grow at the highest CAGR during the forecast period.
EtherCAT is an industrial real-time Ethernet technology, which was developed by Beckhoff Automation (Germany). It is suitable for hard and flexible real-time requirements in automation technology, test and measurement, and many other applications in the manufacturing, metal forming, and assembly systems industries.

These industries require high data integrity, secure data transfer and synchronization. EtherCAT has been specially designed for rapid control demand applications.

It can provide scalable connectivity for entire automation systems, from large PLCs to I / O and sensor level. EtherCAT is an optimized protocol for process data, using standard IEEE 802.3 Ethernet frames.

The automotive and transportation end-use industry accounted for the largest share of the Industrial Ethernet market during the forecast period
Automotive is one of the largest end-use industries for industrial Ethernet and is expected to continue to dominate the market due to the growing need for advanced automation in automotive manufacturing centers around the world. critical components of water treatment systems and an industrial Ethernet network is used to facilitate communication between these systems.

In the automotive industry, Ethernet (IEEE 802.3) is a widely used protocol. In this industry, many processes are controlled by computers and Ethernet is one of the most suitable protocols for computer aided communication. This technology is mainly used for diagnostics, machine control and factory automation, as well as for remote sensor connection. It has the capacity to handle a large amount of data traffic on a single infrastructure.

In-depth interviews were conducted with General Managers (CEOs), Marketing Directors, other Innovation and Technology Directors, and executives from various key organizations operating in the Industrial Ethernet market.

• By type of company: Tier 1 – 18%, Tier 2 – 22% and Tier 3 – 60%
• By designation: C-level senior executives – 21%, managers – 35% and others – 44%
• By region: North America – 22%, Europe – 26%, APAC – 39% and RoW – 13%

Siemens (Germany), Rockwell Automation (United States), Cisco (United States), Belden (United States), Omron (Japan), Moxa (Taiwan), Huawei Technologies (Sweden), SICK (Germany), Schneider Electric (France) and ABB (Switzerland) are the main players in the industrial Ethernet market. These leading players have strong product and service portfolios and are present in mature and emerging markets.

The study includes an in-depth competitive analysis of these key players in the Industrial Ethernet market, with their company profiles, recent developments, and key market strategies.

Research coverage
The report defines, describes, and forecasts the Industrial Ethernet market based on supply, protocol, vertical usage, and geography, and provides detailed information on factors such as drivers, restraints, the opportunities and challenges influencing the growth of the industrial ethernet market.

It also analyzes competitive developments such as product launches, acquisitions, extensions, contracts, partnerships and developments made by major players to expand in the market.

Key benefits of purchasing the report
The report will help the market leaders / new entrants in this market with information on the closest approximations to the revenue figures for the entire Industrial Ethernet market and sub-segments.This report will help stakeholders to understand the landscape competitive edge and obtain more information to better position their businesses and plan appropriate marketing strategies.

The report also helps stakeholders understand the market pulse and provides them with insights into the major market drivers, restraints, challenges, and opportunities.
Read the full report: https://www.reportlinker.com/p04412111/?utm_source=GNW

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


Source link

]]>
https://annonce-fr.com/the-industrial-ethernet-market-was-valued-at-usd-9-2-billion-in-2020-and-is-expected-to-reach-usd-13-7-billion-by-2026-it-is-expected-to-grow-at-a-cagr-of-7-3/feed/ 0